Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanxi Dayu Biological Functions Co's EBIT per Share for the
three
months ended in Jun. 2026 was ¥-0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-0.38.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Shanxi Dayu Biological Functions Co was 43.20% per year. The lowest was -74.90% per year. And the median was 9.05% per year.
BJSE:920970's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Shanxi Dayu Biological Functions Co (BJSE:920970) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Shanxi Dayu Biological Functions Co EBIT per Share Related Terms
Shanxi Dayu Biological Functions Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Dayu Biological Functions Co (BJSE:920970) has a EBIT per Share of ¥-0.38 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shanxi Dayu Biological Functions Co and its competitors. According to the industry distribution chart, Shanxi Dayu Biological Functions Co ranks #999999 out of 1169 companies in the Biotechnology industry.
Is Shanxi Dayu Biological Functions Co's EBIT per Share too high?
Shanxi Dayu Biological Functions Co's current EBIT per Share is ¥-0.38. Based on the distribution chart, Shanxi Dayu Biological Functions Co ranks #999999 out of 1169 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanxi Dayu Biological Functions Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanxi Dayu Biological Functions Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanxi Dayu Biological Functions Co ranks #999999 out of 1169 companies for EBIT per Share. This places Shanxi Dayu Biological Functions Co in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shanxi Dayu Biological Functions Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanxi Dayu Biological Functions Co's current EBIT per Share is ¥-0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Dayu Biological Functions Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co (BJSE:920970) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.25, compared to a current price of ¥6.81 — trading 6.1% below its estimated fair value. The current EBIT per Share is ¥-0.38. Shanxi Dayu Biological Functions Co's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Shanxi Dayu Biological Functions Co (BJSE:920970), the current EBIT per Share is ¥-0.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Dayu Biological Functions Co (BJSE:920970) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Dayu Biological Functions Co stock appears to be undervalued.
The current stock price of ¥6.81 is trading 6.1% below its estimated GF Value™ of ¥7.25.
GuruFocus considers Shanxi Dayu Biological Functions Co to be Fairly Valued.
Key valuation signals for BJSE:920970:
EBIT per Share: ¥-0.38
GF Value™: ¥7.25 vs. price of ¥6.81 (6.1% below fair value)
No single metric tells the full story. See the BJSE:920970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Dayu Biological Functions Co Ltd engages in the research and development of bioengineering technology and product application. Its main products are probiotics, enzyme preparations, fermented traditional Chinese medicine, biological preparations, and veterinary preparations.
63GF Score
Get the complete analysis for BJSE:920970
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920970 has been successfully added to your 
